Page 7 - Haematologica Vol. 109 - July 2024

Non-Hodgkin Lymphoma
2177 Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma
M.J. Maurer et al.
https://doi.org/10.3324/haematol.2023.283737
Non-Hodgkin Lymphoma
2186 Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy
A.M. Tun et al.
https://doi.org/10.3324/haematol.2023.284704
Non-Hodgkin Lymphoma
2196 Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease M. Sarmiento Bustamante et al.
https://doi.org/10.3324/haematol.2023.283603
Plasma Cell Disorders
2207 Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma D. Shin et al.
https://doi.org/10.3324/haematol.2023.283784
Plasma Cell Disorders
2219 Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM- SELIBORDARA study
V. González-Calle et al.
https://doi.org/10.3324/haematol.2023.284089
Plasma Cell Disorders
2229 Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study S. Ninkovic et al.
https://doi.org/10.3324/haematol.2023.284238
Plasma Cell Disorders
2239 Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
P.G. Richardson et al.
https://doi.org/10.3324/haematol.2023.284325
Plasma Cell Disorders
2250 Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden
S. Rögnvaldsson et al. https://doi.org/10.3324/haematol.2023.284365
Platelet Biology & its Disorders
2256 GPIbα CAAR T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia
J. Zhou et al. https://doi.org/10.3324/haematol.2023.283874
Letters to the Editor
2271 Pubertal development of transfusion-dependent thalassemia patients in the era of oral chelation with deferasirox: results from the French registry
M. Veneziano Broccia et al.
https://doi.org/10.3324/haematol.2023.283610
Haematologica | 109 July 2024
III